Regeneron Pharma (REGN) PT Raised to $761 at Baird

July 31, 2026 7:21 AM

Baird analyst Brian Skorney raised the price target on Regeneron Pharma (NASDAQ: REGN) to $761.00 (from $742.00) while maintaining a Neutral rating.

No results found